Zydus Lifesciences gets nod from Health Canada for Liothyronine tablets

Liothyronine, a synthetic form of the thyroid hormone T3 (triiodothyronine), is primarily used to treat hypothyroidism. The tablets will be manufactured at Zydus’ Ahmedabad SEZ facility.
Zydus Lifesciences gets nod from Health Canada for Liothyronine tablets
The project is expected to drive breakthroughs in various fields, including life sciences, materials, cryptography, and more. It will also enable high-end job creation, talent development and global investment inflows into the emerging quantum industry of the country.
Profile Image
CNBCTV18·author
Published Oct 06, 2025   |   8:29 AM GMT-04
Share
·
Add us onAdd us on Google
Zydus Lifesciences Ltd said on Monday it has received a Notice of Compliance (NOC) from Health Canada for its generic Liothyronine tablets in 5 mcg and 25 mcg strengths.

Liothyronine, a synthetic form of the thyroid hormone T3 (triiodothyronine), is primarily used to treat hypothyroidism. The tablets will be manufactured at Zydus’ Ahmedabad SEZ facility.

The product had annual sales of 10.9 million Canadian dollars in Canada, according to IQVIA MAT data for June 2025.

Zydus, including its subsidiaries and affiliates, said the approval will enable it to market the drug in Canada, expanding its footprint in the North American generics market.
Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy